A Phase 2, Randomized, Open-Label Study of Bosutinib Administered in Combination With Exemestane Versus Exemestane Alone as Second Line Therapy in Postmenopausal Women With Locally Advanced or Metastatic ER+/PgR+/ErbB2- Breast Cancer.

Trial Profile

A Phase 2, Randomized, Open-Label Study of Bosutinib Administered in Combination With Exemestane Versus Exemestane Alone as Second Line Therapy in Postmenopausal Women With Locally Advanced or Metastatic ER+/PgR+/ErbB2- Breast Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2016

At a glance

  • Drugs Exemestane (Primary) ; Bosutinib
  • Indications Advanced breast cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 15 Feb 2012 Additional locations added as reported by Clinical Trials Registry - India record.
    • 29 Aug 2011 Planned end date changed from Jul 2011 to Sep 2011 as reported by ClinicalTrials.gov.
    • 07 Jun 2011 Status changed from active, no longer recruiting to discontinued, due to lower than expected efficacy and an increased incidence of liver transaminase elevations
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top